Gallium Ga 68 Gozetotide

Phase 3Radiopharmaceutical

MMayo Clinic

Gallium Ga 68 Gozetotide is one of 39 small molecule programs targeting Prostate Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Prostate CancerCompleted

Prostate Cancer (adenocarcinoma)Not yet recruiting

Prostate CancerPhase 3

Completed

Prostate Cancer (adenocarcinoma)Preclinical

Not yet recruiting

Competition

Competitive Landscape

314 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 3

21 2

Opdivo

Bristol-Myers Squibb

Phase 3

21 3

Lupron

EEastern Cooperative Oncology Group

Phase 3

53 4

Nizoral

WWim Janssens

Phase 3

21 5

Tecentriq

Roche

Phase 3

6 6

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

4 7

Gallium Ga 68 Gozetotide

MMayo Clinic

Phase 3

3 8

Trexall

Jazz Pharmaceuticals

Preclinical

—9

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Preclinical

2 10

Duragesic

CCephalon

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

PreclinicalNot yet recruiting

Prostate Cancer (adenocarcinoma)

NCT07747493

Q3 2030

Phase 2Active, not recruiting

Prostate Cancer

NCT04777071

Clinical

Trials by Indication[1]

Prostate Cancer3 trials

68Ga-PSMA-11 PET/CT Screening Prior to 177Lu-PSMA-617 Therapy for Patients With Metastatic Castrate Resistant Prostate Cancer

Completed·MMayo Clinic·Phase 3·NCT05547386·163 enrolled

Effect of Androgen Receptor Signaling Inhibitors on 68Ga-PSMA-11 PET/CT Imaging in Patients With Castration-Resistant Prostate Cancer

Terminated·JJonsson Comprehensive Cancer Center·Phase 1·NCT04279561·9 enrolled

An Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate Cancer

Active, not recruiting·UUniversity of Washington·Phase 2·NCT04777071·141 enrolled

Breast Cancer1 trial

Fluciclovine and PSMA PET/CT for the Classification and Improved Staging of Invasive Lobular Breast Cancer

Completed·EEmory University·Phase 1·NCT04750473·20 enrolled

Liver Cancer1 trial

PSMA PET/MRI or PSMA PET/CT for Evaluation of Liver Cancer

Completed·MMayo Clinic·Phase 1·NCT04310540·42 enrolled

Advanced Hepatocellular Carcinoma1 trial

Optimizing Outcomes of Patients With Advanced HCC Undergoing Immunotherapy Through Novel 68Ga PSMA PET Imaging

Completed·MMayo Clinic·Phase 2·NCT05176223·26 enrolled

Hepatocellular Carcinoma1 trial

Early Detection, Accurate Staging, and Biologic Characterization of HCC With Hybrid 68Ga-PSMA-Dual -Contrast PET/MRI and PET/CT Using Cyclotron-Produced 68Ga

Completed·MMayo Clinic·Phase 2·NCT04762888·52 enrolled

1 more indication

Prostate Cancer (Adenocarcinoma)1 trial

The Role of 68Ga-PSMA-11 PSMA PET/MRI in Selecting Patients With Prostate Cancer for Focal Therapy: A Pilot Study

Not yet recruiting·UUniversity Health Network, Toronto·Preclinical·NCT07747493·8 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Gallium Ga 68 Gozetotide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Gallium Ga 68 Gozetotide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Gallium Ga 68 Gozetotide. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Mayo Clinic company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Radiopharmaceutical[2]
Highest Phase: Phase 3[1]
Company: MMayo Clinic

Gallium Ga 68 Gozetotide

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q3 2030

Trials by Indication[1]

Prostate Cancer3 trials

Breast Cancer1 trial

Liver Cancer1 trial

Advanced Hepatocellular Carcinoma1 trial

Hepatocellular Carcinoma1 trial

Prostate Cancer (Adenocarcinoma)1 trial

References

Drug Info

Quick Facts

Related News